By WSJ Staff
U.K.-listed drug maker Shire PLC has rejected a GBP27.2 billion ($46.35 billion) takeover bid from U.S. rival AbbVie Inc.
AbbVie (ABBV) said Friday that it had made three cash and share proposals to the board of Shire, with the latest valued at GBP46.26 ($78.87) for each Shire (SHPGY) share, based on AbbVie's closing share price of $54.03 on May 29.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.